To evaluate the impact of AD and LATE pathology on cryptic exon (CE) inclusion that results from TDP-43 dysfunction, we quantified the relative expression of CE-containing transcripts across control, AD, LATE, and AD+LATE groups. The gene discussed is TARDBP; the disease is Alzheimer disease.